Cargando…

Health status in the TORCH study of COPD: treatment efficacy and other determinants of change

BACKGROUND: Little is known about factors that determine health status decline in clinical trials of COPD. OBJECTIVES: To examine health status changes over 3 years in the TORCH study of salmeterol+fluticasone propionate (SFC) vs. salmeterol alone, fluticasone propionate alone or placebo. METHODS: S...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jones, Paul W, Anderson, Julie A, Calverley, Peter MA, Celli, Bartolome R, Ferguson, Gary T, Jenkins, Christine, Yates, Julie C, Vestbo, Jørgen, Spencer, Michael D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3117702/ https://www.ncbi.nlm.nih.gov/pubmed/21627828 http://dx.doi.org/10.1186/1465-9921-12-71

Ejemplares similares

Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study
por: Jenkins, Christine R, et al.
Publicado: (2009)

The severity of airways obstruction as a determinant of treatment response in COPD
por: Calverley, Peter MA, et al.
Publicado: (2006)

Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk
por: Brook, Robert D, et al.
Publicado: (2017)

Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial
por: Celli, Bartolome R, et al.
Publicado: (2019)

FEV(1) is a stronger mortality predictor than FVC in patients with moderate COPD and with an increased risk for cardiovascular disease
por: Bikov, Andras, et al.
Publicado: (2020)

Characterisation of COPD heterogeneity in the ECLIPSE cohort
por: Agusti, Alvar, et al.
Publicado: (2010)

International Differences in the Frequency of Chronic Obstructive Pulmonary Disease Exacerbations Reported in Three Clinical Trials
por: Calverley, Peter M. A., et al.
Publicado: (2022)

Challenging the obesity paradox: extreme obesity and COPD mortality in the SUMMIT trial
por: Brigham, Emily P., et al.
Publicado: (2021)

Pharmacotherapy and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease. A Systematic Review
por: Celli, Bartolome R., et al.
Publicado: (2021)

Impact of pre-enrolment medication use on clinical outcomes in SUMMIT
por: Vestbo, Jørgen, et al.
Publicado: (2019)

Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial
por: Byrd, James Brian, et al.
Publicado: (2018)

Prevention of COPD exacerbations: medications and other controversies
por: Vestbo, Jørgen, et al.
Publicado: (2015)

Markers of disease activity in COPD: an 8-year mortality study in the ECLIPSE cohort
por: Celli, Bartolome, et al.
Publicado: (2021)

Status of the TORCH Project
por: Harnew, N., et al.
Publicado: (2020)

Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype
por: Agustí, Alvar, et al.
Publicado: (2012)

Reigniting the TORCH: Chronic Obstructive Pulmonary Disease Mortality and Inhaled Corticosteroids Revisited
por: Calverley, Peter
Publicado: (2021)

Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease
por: Adamson, Philip D., et al.
Publicado: (2018)

Status of the TORCH time-of-flight project
por: Harnew, N., et al.
Publicado: (2018)

Status of the TORCH time-of-flight detector
por: Harnew, N, et al.
Publicado: (2017)

Status of the TORCH time-of-flight detector
por: Hadavizadeh, Tom, et al.
Publicado: (2020)

Factors associated with change in exacerbation frequency in COPD
por: Donaldson, Gavin C, et al.
Publicado: (2013)

A systematic evaluation of the diagnostic criteria for COPD and exacerbations used in randomised controlled trials on the management of COPD exacerbations
por: Mathioudakis, Alexander G., et al.
Publicado: (2019)

The TORCH detector R&D: Status and perspectives
por: Gys, T, et al.
Publicado: (2017)

The TORCH R&D Project Status and Perspectives
por: Gys, Thierry
Publicado: (2016)

Recommendations for the early diagnosis of COPD: the AIMAR view
por: Celli, Bartolome R
Publicado: (2015)

COPD as an endothelial disorder: endothelial injury linking lesions in the lungs and other organs? (2017 Grover Conference Series)
por: Polverino, Francesca, et al.
Publicado: (2018)

Natural history of COPD: gaps and opportunities
por: Agustí, Alvar, et al.
Publicado: (2017)

Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT(®) studies
por: Miravitlles, Marc, et al.
Publicado: (2009)

The TORCH project
por: Forty, R
Publicado: (2014)

TORCH Reconstruction
por: Rademacker, Jonas
Publicado: (2022)

TORCH simulation
por: Blake, Thomas, et al.
Publicado: (2022)

Passing the Torch
por: McFadden, Grant
Publicado: (2020)

COPD: time to improve its taxonomy?
por: Celli, Bartolomé R., et al.
Publicado: (2018)

TORCH particle identification performance
por: Blake, Thomas, et al.
Publicado: (2022)

Biomarkers of systemic inflammation and depression and fatigue in moderate clinically stable COPD
por: Al-shair, Khaled, et al.
Publicado: (2011)

Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT
por: Putcha, Nirupama, et al.
Publicado: (2022)

Outcomes reported on the management of COPD exacerbations: a systematic survey of randomised controlled trials
por: Mathioudakis, Alexander G., et al.
Publicado: (2019)

Venous Admixture in COPD: Pathophysiology and Therapeutic Approaches
por: Cooper, Christopher B., et al.
Publicado: (2009)

Impact of the UK lockdown on people at risk of COPD
por: Donaldson, Gavin C., et al.
Publicado: (2021)

Mastering PyTorch
por: Jha, Ashish, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kgnpkqnav007vqqt4a9nb8ukcj